Molecular targeted therapy in prevalent tumors: learning from the past and future perspectives.
Important advances have been achieved with molecular targeted agents in clinical oncology. Breast, colon, and lung cancer, are now commonly treated with a combination of chemotherapy and targeted agents. In this article the authors discuss the limitations of targeted therapy development, failures of previous studies, and possible strategies for an intelligent drug development. Initial attempts to block mTOR in breast cancer, the magnitude of benefit obtained with anti-EGFR therapy in lung cancer, and the narrowing use of anti-EGFR therapy in colon cancer based on KRAS status are discussed.
Metzger-Filho
Otto
O
Medical Oncology Clinic, Jules Bordet Institute, Brussels, Belgium.
Moulin
Camilo
C
Awada
Ahmad
A
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism; D005544:Forecasting; D006801:Humans; D058990:Molecular Targeted Therapy / Q000639:trends; D009369:Neoplasms / Q000188:drug therapy*; D057285:Precision Medicine / Q000639:trends; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism
D000970:Antineoplastic Agents; D066246:ErbB Receptors; D058570:TOR Serine-Threonine Kinases